Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income$623.46K$623.46Kderived−54.1% vs Q4 2020 EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$12,391,812+44.0% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Incomederived$621,079−54.2% Operating Cash Flowderived-$1,334,543N/M Free Cash Flowderived-$1,372,300N/M ended Dec 31, 2021 · filed Feb 28, 2022 · 59 d after period end